UPDATE: ProstACT Global Phase 3 Trial for TLX591 Dosed The First Patient
ProstACT Global is a pivotal randomized Phase 3 study testing the PSMA-targeted radiopharmaceutical TLX591 (lutetium‑177 rosopatamab tetraxetan) in metastatic castration‑resistant prostate cancer. The trial has just moved into its randomized expansion phase, with the first patient in this part dosed at a specialized prostate cancer center in Melbourne, marking a key transition from safety/dosimetry work […]
